Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III

J. Cox-Brinkman, M.J. van Breemen, B.T. van Maldegem, L. Bour, W.E. Donker, C.E.M. Hollak, F.A. Wijburg*, J.M.F.G. Aerts

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

30 Citations (Scopus)

Abstract

We report three siblings with Gaucher disease type III, born between 1992 and 2004. During this period, new developments resulted in different potential therapies, changing clinical practice. The two eldest siblings received enzyme replacement therapy (ERT) from the age of 24 and 5 months respectively, later followed by an increase in dosage. ERT was combined with substrate reduction therapy (SRT) from the ages of 12 and 8 years, respectively. In the youngest sibling the combination of high-dose ERT and SRT was given from the age of 5 months. The two eldest siblings showed significant neurological impairment from the age of 1.5 years, starting with a convergent strabismus and partial oculomotor apraxia, followed by cognitive decline and an abnormal EEG and BAER. In contrast, the neurological development in the youngest sibling is almost completely normal. At the age of 3 years, cognitive development, EEG and BAER are all normal. Disturbed saccadic eye movements, which were already present at the start of therapy, remained stable. In addition to the clinical efficacy, we report on the biochemical response to therapy. Based on our results, the combination of high-dose ERT and SRT should be considered as a possible therapeutic approach for GD III, especially if started at a young age. Further follow-up studies are necessary to explore the long-term therapeutic effects.

Original languageEnglish
Pages (from-to)745-752
Number of pages8
JournalJournal of Inherited Metabolic Disease
Volume31
Issue number6
DOIs
Publication statusPublished - 13 Oct 2008
Externally publishedYes

Fingerprint Dive into the research topics of 'Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III'. Together they form a unique fingerprint.

Cite this